SynthesisBritish journal of cancer2026
Clinicopathological and prognostic significance of mucin signatures in lower gastrointestinal cancer-a systematic review and meta-analysis.
Synthesis in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Diagnostic Significance of Ki-67, p53, and Mucin Glycoprotein Expression in Colorectal Serrated Lesions: Further Immunohistochemical Studies.Diagnostics (Basel, Switzerland) · 2026Article
- The Power of MUC2 in Mucinous Adenocarcinomas.Pathobiology : journal of immunopathology, molecular and cellular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Aberrant mucin expression is implicated in lower gastrointestinal tract (GIT) cancers, yet its clinicopathological relevance remains poorly understood. To identify distinct mucin signatures in association with (pre)tumour subtypes, anatomical location, and clinical outcomes, we conducted a systematic review and meta-analysis of MEDLINE articles published between January 2001 and September 2025. Studies were included if they assessed mucin expression in lower GIT (pre)malignant lesions. Fifty-eight studies were eligible. MUC2 and MUC5AC expression was upregulated in serrated polyps and mucinous- and microsatellite instability (MSI)-associated proximal adenocarcinomas, whereas a downregulation of MUC2 was noted in advanced adenomas and non-mucinous distal tumours. Discrepancies in survival in relation to high-level or low-level MUC2 further suggested that this glycoprotein cooperates with other mucins during carcinogenesis. Notably, abundant MUC1 expression was seen in adenomas with high-grade dysplasia and together with high-level MUC13 correlated with (non-)mucinous CRC types and poor prognosis. Similar mucin signatures were also found in small intestinal adenocarcinoma, yet MUC2 was downregulated and increased MUC5AC rather associated with a worse survival, emphasizing the role of tumour location in influencing tumour behaviour. In conclusion, aberrant mucin signatures reflect distinct molecular pathways in (pre)malignant GIT lesions and highlight their potential utility as biomarkers and therapeutic targets. Schematic representation of the main findings regarding altered mucin signalling in several precancerous lesions (adenomatous (i.e., conventional pathway 1) and serrated polyps (i.e. pathway 2)) and small intestinal (SIA) and colorectal (CRC) adenocarcinomas and its clinicopathological significance (outcome, anatomical location (proximal/distal), molecular subtypes (MSI, (non)-mucinous).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.